We have over 20 years experience in delivering humanized antibodies by CDR grafting, the most successful humanization process
Antibody humanization is a rapid and reliable developmental process which offers:
- Short clinical developmental times
- High regulatory approval rates
- Better management of risk
Our Therapeutic Antibody Group (part of MRCTs Centre for Therapeutics Discovery) has substantial antibody engineering know-how. To take advantage of our expertise please contact Dr John Kelly or complete this form.
Humanized antibodies to novel targets
MRCT humanizes antibodies from a range of academic sources at its own risk and licences these with pre-clinical proof of concept.
Previous projects include:
- An anti-HCV antibody with unique sub-type specificity
- An anti-IL25 antibody with demonstrated efficacy in an animal model of allergic asthma
About antibody humanization
Today, antibody humanization is a clinically validated technology. Fourteen humanized antibodies have already obtained market approval with over 80 or more in clinical trials.
Antibody humanisation remains the dominant technology for the development of therapeutic antibodies.
In 2009 therapeutic antibodies produced revenues well in excess of US$36 billion, nearly half of which was generated by humanized antibodies. Between 2007 and 2013, revenue for therapeutic antibodies is forecast to grow by a CAGR of 10.9% to nearly $50 billion.
Our humanization services
- Generating mouse monoclonal antibodies to specific antigens
- Advising on candidate selection
- Humanizing your candidate monoclonals and delivering a regulatory compliant package
Enquire about our humanzing services
To take advantage of our antibody humanization expertise please contact Dr Michael Dalrymple
Our humanization process
MONTHS 1-3
TAG scientists will not only clone & sequence the mouse variable region genes, enabling them to design the humanized antibody variants, but also make and test a chimeric version of the antibody.
- PCR-clone & DNA sequence mouse variable region genes
- Design, construct and test chimeric antibody
- Design of the humanized antibody variable regions
MONTHS 4-6
Scientists will construct and analyse several humanized antibody variants in an iterative process to generate the optimal humanized antibody against your target antigen:
- Analysis & optimisation of the humanized antibody
- Construct and analyse a panel of humanized antibody variants
- Deliver your clinical candidate